European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(Suppl 1):S1–S753. 10.1007/s00259-020-04988-4.
Afshar-Oromieh, A. et al. Performance of [68 Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. 10.1007/s00259-021-05189-3.
Pauwels E, et al. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47:3033–46. DOI: 10.1007/s00259-020-04918-4
Rottenburger C, et al. Cholecystokinin 2 receptor agonist 177 Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma: results of the Lumed Phase 0a Study. 2020. 10.2967/jnumed.119.233031.
Orevi M, et al. [18F]-FDHT PET/CT as a tool for imaging androgen receptor expression in high-grade glioma. Neuro-Oncology Adv. 2021. 10.1093/noajnl/vdab019.
Petrik M, et al. 68Ga-labelled desferrioxamine-B for bacterial infection imaging. Eur J Nucl Med Mol Imaging. 2021;48:372–82. DOI: 10.1007/s00259-020-04948-y